Navigation Links
New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years

DÿSSELDORF, Germany, February 23 /PRNewswire/ -- An international team of researchers has evaluated the effectiveness of Orthokine therapy for osteoarthritis of the knee, and the results have been published in the February edition of the specialist journal "Osteoarthritis and Cartilage". The researchers followed 376 patients to determine the effectiveness of various osteoarthritis treatments. After six months as well as after two years, patients who received Orthokine therapy experienced significantly less pain and more improved joint function than those who received hyaluronic acid or a placebo. Orthokine therapy is a biotechnology-based method in which proteins that inhibit inflammation are obtained from the patient's own blood and injected into the affected joint.

"In this study and for several thousand patients whom we have treated, Orthokine has proven an extraordinarily safe and effective way of treating osteoarthritis of the knee. I am delighted that distinguished experts have now confirmed these findings," said Dr. Peter Wehling, CEO of ORTHOGEN AG, in Düsseldorf on February 21. "We are now planning to distribute the IP-protected Orthokine technology world- wide. Orthokine is already being distributed in various EU countries through ORTHOGEN or other distributors."

Orthokine is the first scientifically proven, placebo-controlled autologous therapy in the orthopaedic field.

This kind of therapy was recently discussed in The New York Times. Two of the Pittsburgh Steelers' biggest stars, Hines Ward and Troy Polamalu, used their own blood cells in an innovative injury treatment before winning the Super Bowl.

    To find out more:

    For more information please contact:
    Orthogen AG
    Press and Public Relations
    Elena Kawadopulos
    Graf-Adolf-Str. 43
    40210 Düsseldorf
    Tel.: +49-211-3670076
    Fax: +49-211-3670010
    Mobile: +49-177-588-3442

SOURCE Orthogen AG
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads
2. American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks
3. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
4. Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder
5. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
6. Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis
9. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
10. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
11. Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease
Post Your Comments:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
Breaking Medicine Technology:
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
Breaking Medicine News(10 mins):